

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Breakthrough innovation & insight

Brii Biosciences Limited

騰盛博藥生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2137)

VOLUNTARY ANNOUNCEMENT

Launch of BRiSC™, an siRNA Therapeutics Discovery Platform

This announcement is made by the board of directors (the “**Board**”) of Brii Biosciences Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce the launch of **BRiSC™ (Bispecific RNAi SilenCing)**, a proprietary small interfering ribonucleic acid (“**siRNA**”) therapeutics discovery platform to advance the discovery and development of next-generation ribonucleic acid (“**RNA**”)–based therapies.

BRiSC™ integrates a suite of four complementary technologies spanning sequence optimization, chemical modification, dual-targeting architectures, and targeted delivery approaches. Collectively, these complementary capabilities are designed to enhance the selectivity, performance and therapeutic reach of siRNA medicines, supporting the development of differentiated therapies for a broad range of diseases.

Through continued investment in its internal discovery organization, laboratories in Beijing and Shanghai, and RNA technology capabilities, the Company has expanded its internal research and development capabilities across target discovery, translational science, and preclinical development. These capabilities serve as the foundation for BRiSC™, which is already driving the progression of multiple internal discovery programs.

As one of BRiSC™’s core capabilities, the dual-targeting architecture is designed to enable a single siRNA therapeutic to simultaneously silence two distinct targets, addressing diseases driven by multiple biologic pathways, through a single treatment. The Company is initially applying this approach to prevalent disease areas where complex biology and/or overlapping comorbidities may potentially benefit from coordinated modulation of multiple therapeutic targets.

“BRiSC™ reflects our commitment to building differentiated scientific capabilities across multiple dimensions of siRNA therapeutic discovery and development,” said Dr. Brian Johns, Chief Science Officer of the Company. “Our dual-targeting platform exemplifies this approach by combining innovative molecular design with deep insights into disease biology to address conditions driven by multiple unique pathways. Our goal is to develop differentiated RNA therapeutics that can deliver broader and more meaningful benefits for patients”, he added.

Cautionary Statement: The BRiSC™ platform and the related internally discovered programs described in this announcement are at various stages of research and development. There is no assurance that the platform will generate viable therapeutic candidates, that any candidate will progress into or through clinical development, or that it will ultimately obtain regulatory approval or be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, October 15, 2026

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive Directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive Directors.